No Data
Eiken Chemical - a comprehensive manufacturer of clinical diagnostic reagents, holds the top Share in fecal occult blood test reagents and aims for growth through Overseas expansion and M&A implementation.
Eiken Chemical Co., Ltd. <4549> is a comprehensive manufacturer of clinical testing reagents, handling clinical test reagents and equipment used in various fields such as fecal occult blood tests for colorectal cancer screening, urine tests at Hospitals and health checkups, and diagnostic tests for infections. It offers a wide range of clinical testing reagents and equipment used in various diagnostics, including microbiological tests, immunoserological tests, and rapid tests (POCT), with its fecal occult blood test reagents and urine test reagents boasting the top Share in the domestic market. In Japan, it holds the leading share in fecal occult blood test reagents.
Eiken Chemical: Interim report.
Towns - The interim financial results for the period ending June 2025 confirm good performance, supporting the undervaluation of stock prices.
Towns <197A>, which has strengths in core technologies such as antibody-related technologies and "platinum-gold colloid" technology, as well as multiple development achievements of products that are the "first in the world" in the field of testing for mycobacteria such as tuberculosis, reported its interim financial results for the period ending June 2025, showing a revenue of 11,981 million yen, a 3.1% increase compared to the same period last year, and an operating profit of 6,538 million yen, an 11.7% increase, reflecting significant growth in both revenue and profit. In the second quarter alone, the figures show a revenue increase of 19.0% and a profit increase of 32.5%, indicating extremely high growth. Contributions from influenza.
Express News | [Change Report] NIPPON ACTIVE reported an increase in the Shareholding ratio of Eiken Chemicals (4549.JP) to 24.69%.
Hitachi, upward revision on March 25, operating profit 930 billion yen, up from 875 billion yen.
Hitachi <9501> announced a revision of the performance forecast for the fiscal year ending March 2025. Revenue has been revised upward from 9 trillion 150 billion yen to 9 trillion 700 billion yen, and operating profit has been increased from 875 billion yen to 930 billion yen. The revenue of its subsidiary, Hitachi Energy, engaged in power transmission and distribution networks, is growing, and the "Lumada" business that supports corporate digital transformation (DX) is also performing well. The depreciation of the yen against the Exchange Rates (1 dollar = 145 yen) is also boosting revenue. [Positive Assessment] <95
Eiken Chemical Sees FY Net Y2.62B